Atopic Dermatitis Gets a Treatment Revolution With New Biologics and JAK Inhibitors
A 2025 review maps the expanding arsenal of FDA-approved and investigational therapies for atopic dermatitis across all ages.
Summary
A comprehensive 2025 review from Northwestern University evaluates newly approved and emerging treatments for atopic dermatitis in both children and adults. Nonsteroidal topical agents roflumilast and tapinarof are now approved for young children. Biologics targeting IL-4/IL-13 — dupilumab, tralokinumab, and lebrikizumab — have expanded age approvals, while nemolizumab now targets the itch-specific IL-31 receptor. Oral JAK inhibitors upadacitinib and abrocitinib are approved in the US for ages 12 and up. On the horizon, microbiome-altering bacteriotherapy and OX40/OX40L pathway agents signal a shift toward personalized treatment. Long-term safety data and predictive treatment models remain priorities.
Detailed Summary
Atopic dermatitis (AD) is one of the most common chronic inflammatory skin conditions, affecting millions across all age groups and significantly impairing quality of life. For decades, treatment options were limited largely to corticosteroids and broad immunosuppressants. A wave of targeted therapies is now reshaping the landscape, and this 2025 review from Northwestern University provides a timely synthesis of where things stand.
The review draws on PubMed literature, clinical trial registries, conference abstracts, and industry data to evaluate both approved and investigational agents. It covers topical, biologic, and oral systemic therapies across pediatric and adult populations, with particular attention to recent FDA approvals and pipeline developments.
Several key approvals stand out. Nonsteroidal topical creams — roflumilast (approved to age 6) and tapinarof (approved to age 2) — offer steroid-sparing options for younger patients. Topical ruxolitinib, a JAK1 inhibitor, provides targeted local action with a favorable safety profile. Among biologics, dupilumab now covers patients as young as 6 months, while tralokinumab and lebrikizumab extend to age 12. Nemolizumab, targeting the IL-31 receptor responsible for nonhistaminergic itch, represents a novel mechanism approved for patients 12 and older. Oral JAK inhibitors upadacitinib and abrocitinib remain the US-approved systemic options for adolescents and adults.
Looking ahead, bacteriotherapy aimed at modulating the skin microbiome and systemic agents targeting the OX40/OX40L costimulatory pathway are in active development, alongside multispecific antibodies that may address multiple inflammatory pathways simultaneously.
The review acknowledges that long-term safety data for many newer agents remain limited, and that predictive biomarkers to guide individualized therapy selection are still lacking. As the field moves toward precision medicine in AD management, ongoing trials and real-world evidence will be critical.
Key Findings
- Tapinarof cream is approved for AD in children as young as 2 years; roflumilast down to age 6.
- Dupilumab now approved for infants 6 months and older; tralokinumab and lebrikizumab approved from age 12.
- Nemolizumab targets IL-31 receptor to address nonhistaminergic itch, approved for patients 12 and older.
- Upadacitinib and abrocitinib are the only oral JAK inhibitors approved in the US for adolescents and adults.
- Investigational bacteriotherapy and OX40/OX40L-targeting agents signal a shift toward personalized AD care.
Methodology
This is a narrative review, not a primary clinical study. Data were sourced from PubMed peer-reviewed publications, ClinicalTrials.gov, scientific meeting abstracts, and industry press releases. The review covers both pediatric and adult populations across topical and systemic treatment categories.
Study Limitations
As a narrative review, this paper is subject to selection bias in source inclusion and does not perform meta-analytic synthesis of efficacy data. Long-term safety data for many recently approved agents remain limited. Predictive biomarkers to guide individualized therapy selection are not yet clinically validated.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.